- Home
- LSBK vs CUE Comparison
LSBK vs CUE Comparison
Compare LSBK & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LSBK | CUE |
|---|---|---|
| Founded | 1891 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.0M | 49.6M |
| IPO Year | 2006 | 2018 |
Fundamental Metrics
Financial Performance| Metric | LSBK | CUE |
|---|---|---|
| Price | $14.86 | $0.38 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 7.7K | ★ 1.7M |
| Earning Date | 01-23-2026 | 11-12-2025 |
| Dividend Yield | ★ 2.42% | N/A |
| EPS Growth | ★ 105.28 | N/A |
| EPS | ★ 1.21 | N/A |
| Revenue | ★ $27,774,000.00 | $7,100,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | $12.32 | ★ N/A |
| Revenue Growth | ★ 9.61 | N/A |
| 52 Week Low | $11.50 | $0.23 |
| 52 Week High | $16.95 | $1.69 |
Technical Indicators
Market Signals| Indicator | LSBK | CUE |
|---|---|---|
| Relative Strength Index (RSI) | 57.93 | 46.75 |
| Support Level | $14.66 | $0.23 |
| Resistance Level | $14.92 | $0.44 |
| Average True Range (ATR) | 0.20 | 0.05 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 76.57 | 75.62 |
Price Performance
Historical ComparisonAbout LSBK Lake Shore Bancorp Inc.
Lake Shore Bancorp Inc operates as a savings and loan holdings company. The bank's business consists of attracting retail deposits from the general public in the areas surrounding its branch offices and investing those deposits, together with funds generated from operations, in commercial real estate loans, one-to-four family residential mortgage loans, home equity lines of credit and to a lesser extent, commercial business loans, consumer loans, and investment securities. Its revenues are principally derived from interest earned on loans and investment securities.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.